PetMed Express (PETS) Q1 2025 earnings summary

Executive summary

• Q1 FY2025 was a transition quarter with a new CEO and several key executive hires, focusing on operational excellence, cost reduction, and digital transformation.

• Strategic initiatives include cost optimization, customer growth, and technology upgrades to reposition for long-term growth and profitability.

• The company markets through national advertising to build brand recognition and drive both new and repeat customer sales.

• The average purchase value was approximately $97 for both Q1 FY25 and Q1 FY24.

• Early signs of improvement in order values, call handling times, and margins, despite Q1 results being below expectations.

Financial highlights

• Net sales for Q1 FY25 were $68 million, down 13.2% year-over-year, mainly due to lower prescription medication sales.

• Gross profit margin declined to 26.4% from 28.8% year-over-year, impacted by higher promotional activity.

• Adjusted EBITDA was a loss of $1.5 million, compared to a $3.1 million gain last year.

• Net income was $3.8 million ($0.18 per diluted share), up from a net loss of $1.1 million last year, due to an $8.7 million stock compensation reversal.

• Cash and equivalents stood at $46 million at quarter-end, down from $55.3 million at March 31, 2024.

Outlook and guidance

• Stabilization in revenue, conversion rates, and margins observed since the end of Q1, with positive trends continuing into Q2.

• New acquisition marketing campaigns launching in August, expected to accelerate sales growth and profitability.

• Management expects the impact of new cost reduction and customer growth initiatives to be more visible in future quarters.

• Macroeconomic factors such as inflation, higher interest rates, and supply chain volatility are expected to continue impacting operations and consumer demand for the remainder of FY25.

• The company expects ongoing challenges in revenue growth due to increased competition and price sensitivity among consumers.